OpenAI acquires Orchestra Bio to boost Rosalind operations
According to OpenAI, the company acquired Orchestra Bio to integrate its coordination platform with Rosalind AI models and tools to streamline biopharma R&D operations.
SourceAnalysis
OpenAI announced the acquisition of Orchestra Bio on October 20, 2026, according to their post on X.
The platform helps biopharma teams coordinate the complex process of drug development and will integrate with Rosalind, OpenAI's AI models and tools for life sciences research, to streamline operations and help new treatments reach patients sooner.
OpenAI
@OpenAILeading AI research organization developing transformative technologies like ChatGPT while pursuing beneficial artificial general intelligence.